Home > News > Industry > Pharma News > GSK settles another...

GSK settles another Zantac lawsuit in California

Written By :  Ruchika Sharma
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-02-01 10:45 GMT   |   Update On 2024-03-22 08:23 GMT

California: GSK said on Thursday it had agreed to settle another lawsuit in California that alleged its discontinued heartburn drug Zantac caused cancer, the latest in a series of settlements to end costly litigation.The case was set to go to trial on Feb. 20 and instead, will now be dismissed, the British drugmaker said in a statement.GSK said the terms of the settlement were confidential...

Login or Register to read the full article
Register Now

California: GSK said on Thursday it had agreed to settle another lawsuit in California that alleged its discontinued heartburn drug Zantac caused cancer, the latest in a series of settlements to end costly litigation.

The case was set to go to trial on Feb. 20 and instead, will now be dismissed, the British drugmaker said in a statement.
GSK said the terms of the settlement were confidential and that it did not admit to any liability.
In 2019, some manufacturers and pharmacies halted Zantac sales over concerns that its active ingredient, ranitidine, degraded over time to form a chemical called NDMA. While NDMA can be present in low levels in food and water, research has found it causes cancer in larger amounts.
The U.S. Food and Drug Administration (FDA) in 2020 pulled Zantac and its generic versions off the market, triggering a wave of lawsuits.
The drug, approved over four decades ago, was the world's best selling medicine in 1988 and one of the first drugs to top $1 billion in annual sales.
As of October, GSK still faced about 79,000 cases related to Zantac in the United States, with 73,000 of them in Delaware.
California is generally seen as a more challenging legal environment for multinational companies as courts are perceived as friendlier to plaintiffs.
Analysts have estimated total settlement costs for GSK of around $5 billion.
Shares in the FTSE 100 firm closed up 2% on Wednesday, after the company beat market estimates for fourth-quarter results, and unveiled an upbeat forecast for 2024 and beyond on the ramp-up of its vaccines and cancer drugs pipeline.
The shares were steady in early Thursday trade.

Read also: Fate of most remaining Zantac lawsuits weighed by Delaware judge

Original news source: https://www.reuters.com/business/healthcare-pharmaceuticals/gsk-confidentially-settles-another-zantac-lawsuit-california-2024-02-01/ 

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

Zydus Lifesciences bags USFDA nod for Dapsone Gel for acne treatment
USFDA approves Alembic Pharma five products in over a month
Lupin ropes in Jeffrey Kindler, Alfonso Zulueta as Independent Directors
Cipla gets 1 inspectional observation from USFDA for Maha facility
USFDA Advisory Committee to convene meeting to discuss on Eli Lilly Alzheimer's drug donanemab
Lupin net profit surges 52 percent at Rs 359 crore in Q4
Surprise check at pharmacies: Noida admin seizes samples of three medicines
Gland Pharma bags USFDA nod for amyotrophic lateral sclerosis injection Edaravone